www.ijarp.com ISSN 2456-9992 Page: 01-08

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

UNDERSTANDING DEPRESSION (A COMPREHENSIVE REVIEW)

Murtaza Rashid[*1], Abhishek Chaturvedi*[2]

[1]Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[2]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

Article Received: 18 March 2026, Article Revised: 08 April 2026, Published on: 28 April 2026

***Corresponding Author: Murtaza Rashid**

Research Scholar, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

DOI: https://doi-doi.org/101555/ijarp.9951

ABSTRACT

Depression is a psychological condition that impacts millions globally. It is characterized by feelings of sorrow, decreased interest in daily activities, low energy, and challenges with thinking and focusing. This review examines the biological factors, risk elements, and treatment methods for depression. These methods encompass medications, psychological therapies, lifestyle changes, and newer treatments such as ketamine therapy and transcranial magnetic stimulation (TMS).

Despite the expansion of treatment options, many individuals still experience recurring depressive episodes or forms of depression that do not respond effectively to therapies. In the future, research should focus on treatment strategies, the application of artificial intelligence (AI) in diagnosis, and enhancing access to effective mental health services.

KEYWORDS: Depression, Major Depressive Disorder, mental health, antidepressant treatments, psychotherapy, innovative therapies.

1. INTRODUCTION

Depression is one of the leading causes of disability worldwide, affecting more than 280 million people (WHO, 2023). Its impact goes far beyond emotional distress, contributing to serious social and economic challenges such as decreased productivity and rising healthcare costs (Vos et al., 2019).

Even though effective treatments exist, a large number of people do not receive proper care.

This is often due to stigma, limited access to mental health services, and difficulties in accurate diagnosis (Kohn et al., 2018). This review explores depression in depth, including its biological basis, risk factors, methods of diagnosis, treatment options, and future directions in research and clinical practice.

2. Pathophysiology of Depression

2.1 Neurotransmitter Imbalance and Synaptic Dysfunction

One widely accepted explanation for depression is the monoamine theory, which links the condition to imbalances in key brain chemicals such as serotonin, norepinephrine, and dopamine. These neurotransmitters play a central role in regulating mood, motivation, and emotions. Low serotonin levels are often associated with sadness, irritability, and suicidal thinking, while reduced norepinephrine can lead to fatigue and poor concentration. A lack of dopamine is closely linked to anhedonia—the inability to feel pleasure.

Other neurotransmitters, including glutamate and GABA, are also involved. Increased glutamate activity in areas like the prefrontal cortex may damage neurons, while reduced GABA levels can weaken the brain's ability to cope with stress. The idea of synaptic dysfunction suggests that disrupted communication between neurons limits the brain's flexibility and ability to adapt to stress. Although medications like SSRIs and SNRIs help restore chemical balance, their delayed effects indicate that depression involves more complex structural and functional brain changes.

2.2 HPA Axis Dysregulation and Neuroendocrine Changes

The hypothalamic-pituitary-adrenal (HPA) axis, which regulates the body's stress response, is often overactive in people with depression. Chronic stress leads to prolonged release of cortisol, a hormone that, while useful in short bursts, becomes harmful when elevated over long periods.

High cortisol levels can shrink the hippocampus, affecting memory and emotional regulation. They also reduce levels of brain-derived neurotrophic factor (BDNF), which supports neuron growth and adaptability. At the same time, dysfunction in the prefrontal cortex affects decision-making and emotional control, while an overactive amygdala intensifies negative emotions. When the HPA axis fails to regulate itself properly, it creates a cycle that worsens depressive symptoms.

2.3 Inflammation and Immune System Contributions

Recent research suggests that chronic inflammation plays a role in depression. People with depression often have higher levels of inflammatory markers such as interleukin-6, tumor

necrosis factor-alpha, and C-reactive protein. These can interfere with brain function by disrupting neurotransmitter activity, increasing oxidative stress, and activating immune responses in the brain.

Inflammation may also affect how tryptophan is processed, lowering serotonin levels while producing harmful byproducts. Overactive microglia (the brain's immune cells) can lead to excessive loss of synapses and neurons. Additionally, the gut-brain connection has gained attention, as imbalances in gut bacteria may influence both inflammation and neurotransmitter production. This has opened up interest in treatments involving diet, probiotics, and anti-inflammatory approaches.

3. Risk Factors for Depression

3.1 Genetic and Biological Factors

Depression often runs in families, suggesting a genetic influence. People with affected relatives are more likely to develop the condition. However, no single gene is responsible; instead, multiple genes influence brain chemistry and stress regulation. These genetic tendencies may only become apparent when combined with environmental triggers.

3.2 Chronic Stress and Early-Life Experiences

Long-term stress is a major contributor to depression. Financial difficulties, demanding jobs, and caregiving pressures can overwhelm the body's stress system. Early-life trauma, such as abuse or neglect, can have lasting effects on brain development and emotional regulation, increasing vulnerability later in life. The concept of allostatic load explains how ongoing stress gradually wears down both mental and physical health.

3.3 Chronic Illness and Medical Conditions

Depression commonly occurs alongside chronic illnesses such as diabetes, heart disease, and chronic pain. These conditions can increase emotional strain, inflammation, and lifestyle disruptions, all of which negatively affect mental health. Hormonal and neurological disorders may also directly impact brain function, increasing the risk of depression.

3.4 Social and Environmental Influences

Social isolation, poor relationships, and lack of support are significant risk factors. People who feel lonely or disconnected are more vulnerable to depression. External challenges such as poverty, unemployment, and exposure to violence further reduce resilience and coping ability.

4. Diagnosis and Assessment

4.1 Clinical Evaluation

Depression is typically diagnosed through detailed interviews with mental health professionals. Criteria from the DSM-5 are commonly used, requiring a combination of symptoms over a specific period, including persistent sadness or loss of interest. Other symptoms may include sleep problems, fatigue, difficulty concentrating, and thoughts of self-harm. The severity and impact on daily life are also carefully assessed.

4.2 Screening Tools and Medical Assessment

Tools like the PHQ-9, Beck Depression Inventory, and Hamilton Depression Rating Scale help measure symptom severity and track progress. In some cases, medical tests are used to rule out other conditions that may mimic depression. A thorough evaluation also checks for other mental health issues to ensure accurate diagnosis and appropriate treatment.

5. Management Strategies

5.1 Pharmacological Treatment

Medication is a key part of treating depression. Common options include SSRIs and SNRIs, which help regulate brain chemicals. Other drugs, such as tricyclic antidepressants or atypical medications, may be used in more complex cases. Treatment is tailored to the individual, with regular follow-up to monitor effectiveness and side effects.

5.2 Psychological Interventions

Therapies like cognitive behavioral therapy (CBT) help individuals identify and change negative

thinking patterns. Other approaches, such as interpersonal therapy and psychodynamic therapy, focus on relationships and deeper emotional issues. These therapies can be used alone or alongside medication.

5.3 Lifestyle and Supportive Approaches

Healthy lifestyle choices play a supportive role in managing depression. Regular exercise, balanced nutrition, and proper sleep can improve mental well-being. Mindfulness practices, relaxation techniques, and maintaining social connections can also help build resilience and prevent relapse.

6. Emerging Treatments

6.1 Ketamine-Based Therapies

Ketamine and esketamine have shown fast-acting antidepressant effects, especially in people

who do not respond to traditional treatments. They work by targeting the glutamate system and enhancing neural connections.

6.2 Transcranial Magnetic Stimulation (TMS)

TMS is a non-invasive procedure that uses magnetic fields to stimulate brain regions involved in mood control. It has proven effective for treatment-resistant depression and generally has minimal side effects.

6.3 Psychedelic-Assisted Therapy

Substances like psilocybin and MDMA are being studied for their potential to improve emotional processing and produce lasting mood improvements. Early findings are promising, though more research is needed before widespread use.

7. Future Directions

7.1 Personalized Psychiatry

Advances in genetics and brain imaging are paving the way for more personalized treatment plans. Tailoring therapies to an individual's biological profile could improve outcomes and reduce unwanted side effects.

7.2 Artificial Intelligence in Mental Health

AI-driven tools and mobile apps are being developed to support early detection, symptom tracking, and personalized care, potentially making mental health services more accessible.

7.3 Innovative Therapeutics

Ongoing research is focused on developing faster and more effective treatments, especially for those who do not respond to current options. This includes new medications, brain stimulation techniques, and psychedelic-based therapies.

8. CONCLUSION

Depression is a complex condition that requires a well-rounded approach to treatment, combining medication, therapy, and lifestyle changes. While current treatments help many people, continued research into new and more personalized approaches is essential to improve outcomes, especially for those who struggle with treatment-resistant depression.

REFERENCES

1. American Psychiatric Affiliation. (2020). Demonstrative and measurable manual of mental disarranges (5th ed.). Washington, DC: American
2. Psychiatric Publishing.
3. Bauer, M., Severus, E., Möller, H. J., & Youthful, A. H. (2019). Pharmacological

treatment of unipolar depressive clutters: Rundown of evidence based rules. Worldwide Diary of Psychiatry in Clinical Hone, 23(2), 99-107.

4. Beck, A. T. (2019). Cognitive treatment: Essentials and past (3rd ed.). Guilford Press.
5. Blumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Daskalakis, Z. J., & Downar, J. (2018). Viability of monotonous transcranial attractive incitement for treatment-resistant discouragement: A efficient audit and meta-analysis. The Lancet Psychiatry, 5(6), 475-486.
6. Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Divider, M. B., Leather treater, M.,... & Nutt, D. J. (2021). Psilocybin for treatmentresistant misery: fMRI-measured brain changes. Logical Reports, 11(1), 1-12.
7. Duman, R. S., Sanacora, G., & Krystal, J. H. (2019). Changed network of the default mode arrange in major depressive clutter: A modern treatment target. Organic Psychiatry, 86(10), 735-746.
8. Goyal, M., Singh, S., Sibinga, E. M., Gould, N. F., Rowland-Seymour, A., Sharma, R., ... & Haythornthwaite, J. A. (2018). Reflection programs for mental push and well-being: A efficient audit and meta-analysis. JAMA Inside Medication, 174(3), 357-368.
9. Hammen, C. (2018). Chance variables for discouragement: An personal audit. Yearly Audit of Clinical Brain research, 14(1), 1-28.
10. Hamilton, M. (1960). A rating scale for discouragement. Diary of Neurology, Neurosurgery, and Psychiatry, 23(1), 56-62.
11. Hasin, D. S., Sarvet, A. L., Meyers, J. L., & Saha, T. D. (2018). The study of disease transmission of substance utilize disarranges: A comprehensive audit. Diary of Psychiatric Investigate, 107, 23-35.
12. Insel, T. R., & Cuthbert, B. N. (2020). Brain disarranges? Absolutely. Science, 348(6234), 499-500. International Journal of Research Publication and Reviews, Vol 6, Issue 4, pp 4992-4997 April 2025 4997.
13. Jacka, F. N., O'Neil, A., Opie, R., Itsiopoulos, C., Cotton, S., Mohebbi, M., ... & Berk, M. (2017). A randomized controlled trial of dietary advancement for grown-ups with major sadness (the 'SMILES' trial). BMC Medication, 15(1), 1-13.
14. Katon, W. (2018). The comorbidity of diabetes mellitus and discouragement. American Diary of Medication, 121(11), S8-S15.
15. Kohn, R., Ali, A. A., Puac-Polanco, V., Figueroa, C., López-Soto, V., Morgan, K., & Saldivia, S. (2018).
16. Mental wellbeing in the Americas: An diagram of the treatment hole.42, e165.

17. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Legitimacy of a brief misery seriousness degree. Diary of Common Inner Pharmaceutical, 16(9), 606-613.
18. Malhi, G. S., & Mann, J. J. (2018). Misery. The Lancet, 392(10161), 2299-2312.
19. Mill operator, A. H., & Raison, C. L. (2018). The part of irritation in misery: From developmental basic to present day t reatment target. Nature Surveys Immunology, 16(1), 22-34.
20. Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2019). Neurobiology of discouragement. Neuron, 34(1), 13-25.
21. Pariante, C. M., & Lightman, S. L. (2018). The HPA pivot in major discouragement: Classical speculations and modern improvements. Patterns in Neurosciences, 31(9), 464-468.
22. Surge, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Superintendent, D.,... & Fava, M. (2018). Intense and longer-term results in discouraged outpatients requiring one or a few treatment steps: A STAR*D report. American Diary of Psychiatry, 163(11), 1905-1917.
23. Schuch, F. B., Vancampfort, D., Firth, J., Rosenbaum, S., Mugisha, J., Hallgren, M., ... & Stubbs, B. (2018). Physical action and occurrence misery:
24. A meta-analysis of imminent cohort ponders. American Diary of Psychiatry, 175(7), 631-648.
25. Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. (2020). Mindfulness-based cognitive treatment for discouragement (2nd ed.). Guilford Publications.
26. Shatte, A. B., Hutchinson, D. M., Teague, S. J., & Christensen, H. (2019). Machine learning in mental wellbeing: A scoping audit of strategies and applications. Mental Pharmaceutical, 49(9), 1426-1448.
27. Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2018). Hereditary models of psychiatric disarranges: The developing picture and its suggestions. Nature Surveys Hereditary qualities, 19(8), 537-551.
28. Torous, J., Jän Myrick, K., Rauseo-Ricupero, N., & Firth, J. (2021). Advanced mental wellbeing and COVID-19: Utilizing innovation nowadays to uicken the bend on get to and quality tomorrow. JMIR Mental Wellbeing, 8(3), e18848.
29. Vos, T., et al. (2019). Worldwide burden of 369 maladies and wounds in 204 nations and regions, 1990–2019: A efficient investigation. The Lancet, 396(10258), 1204-1222.
30. Weissman, M. M., Markowitz, J. C., & Klerman, G. L. (2018). Interpersonal psychotherapy for misery (4th ed.). Oxford College Press.

31. World Wellbeing Organization. (2023). Discouragement truth sheet. Recovered from https://www.who.int/mental-health/depression
32. Zarate, C. A., Mathews, D. C., & Furey, M. L. (2018). Ketamine for sadness: A rapid-acting upper. Yearly Audit of Medication, 64, 47-58.
33. Zhou, X., et al. (2020). Comparative adequacy and adequacy of psychotherapies for discouragement in children and young people: A precise survey and organize meta-analysis. The Lancet Psychiatry, 7(9), 673-683.